Pembrolizumab Plus Bevacizumab and Oral Metronomic Cyclophosphamide for Recurrent Ovarian Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
JAMA Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Efficacy and Safety of Pembrolizumab in Combination With Bevacizumab and Oral Metronomic Cyclophosphamide in the Treatment of Recurrent Ovarian Cancer: A Phase 2 Nonrandomized Clinical Trial
JAMA Oncol 2020 Nov 19;[EPub Ahead of Print], E Zsiros, S Lynam, KM Attwood, C Wang, S Chilakapati, EC Gomez, S Liu, S Akers, S Lele, PJ Frederick, K OdunsiFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.